Search clinical trials for: intermediate risk

Total 15850 results

Supergene, LLC

Not yet recruiting

Non-immunogenic Recombinant Staphylokinase vs Placebo in Patients With Intermediate High-risk Pulmonary Embolism

Pulmonary Embolism

Russian Federation
Rennes University Hospital

Not yet recruiting

Medico-economic Evaluation of Robot-assisted Laparoscopy Compared With Conventional Laparoscopy in Hysterectomy for Endometrial Cancer. (ROBOT-ECO-GYN)

Hysterectomies for Low- or Intermediate-risk Endometrial Carcinoma

France
Hoffmann-La Roche

Recruiting

A Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors With Resectable Disease With Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H) (IMperator)

Solid Tumors

Spain
UroGen Pharma Ltd.

Not yet recruiting

A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer (UTOPIA)

Bladder Cancer | Urothelial Carcinoma Bladder | Urothelial Carcinoma
Unidade Local De Saúde Do Norte Alentejano
NOVA Medical School

Recruiting

Opportunistic Gastric Cancer Screening (ROCGAS)

Gastric Cancer

Portugal
AOP Orphan Pharmaceuticals AG
GCP-Service International Ltd. & Co. KG; ANOVA CRO s.r.o.; PharmaLex Belgium; Aixial...

Recruiting

Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I Patients (TripleTRE)

Pulmonary Arterial Hypertension

Austria, Spain, France, Germany, Italy, Czechia, Hungary, Poland, Portugal, Romania
IRCCS Sacro Cuore Don Calabria di Negrar

Not yet recruiting

Low and Intermediate Risk oliGometastatic coloREctal cancEr patieNts Treated With Stereotactic ABlative Radiotherapy (GREENLaIT-SABR)

Colorectal Cancer

Italy
ANRS, Emerging Infectious Diseases

Not yet recruiting

Impact of Long-acting Injectable Cabotegravir for HIV PrEP in MSM in France. (CABOPrEP)

Prevention

France
M.D. Anderson Cancer Center

Not yet recruiting

Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients

Mantle Cell Lymphoma

United States
British Columbia Cancer Agency
University of British Columbia; Vancouver Prostate Centre; BC Cancer Foundation

Recruiting

Multi-omic Approach to Study HDR Brachytherapy for Favorable Risk and Low Tier Intermediate Risk Prostate Cancer (BrachyTRACKS)

Localized Prostate Carcinoma

Canada
Sunnybrook Health Sciences Centre

Recruiting

De-escalated Dose SBRT in Localized Prostate Cancer (DESTINATION-MRL)

Prostate Cancer

Canada
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
First Affiliated Hospital, Sun Yat-Sen University; First Affiliated Hospital... and other collaborators

Recruiting

TEER for Severe DMR of Low to Intermediate Surgery Risk

Mitral Regurgitation

China
Niguarda Hospital

Recruiting

Ultrasound-assisted, Catheter-directed Thrombolysis for Acute Intermediate-high-risk Pulmonary Embolism (USAT IH-PE)

Pulmonary Embolism

Italy
H. Lee Moffitt Cancer Center and Research Institute

Recruiting

Non-Invasive Biomarkers in Prostate Cancer Disease Management

Prostate Cancer

United States
NHS Lothian

Not yet recruiting

The PRECISION Study: 3 Fractions of Prostate SBRT and RayPilot HypoCath Image Guidance (PRECISION)

Low Risk Prostate Cancer | Intermediate Risk Prostate Cancer | Localized Prostate Cancer
CG Oncology, Inc.

Recruiting

A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

Bladder Cancer | Urothelial Carcinoma | Urologic Cancer | Non Muscle Invasive Bladder Cancer

United States
Yale University
Pfizer

Recruiting

The SUGAR Study: (SBRT and Ultrashort GnRH Antagonist-Relugolix) for Clinicogenomic Unfavorable Intermediate Risk Prostate Cancer

Prostate Cancer

United States
Centre Hospitalier Universitaire de Nīmes

Recruiting

Impact of Training on the Use of Software and Digital Monitoring Tools During General Anesthesia for Intermediate/Major-risk Surgery on Morbidity and Mortality at 28 Days (AoA QUALITY)

All Conditions Requiring Non-cardiac Surgery

France
Lantheus Medical Imaging

Recruiting

PYLARIFY® PET/CT or PET/MRI in Men With Favorable Intermediate Risk (FIR) Prostate Cancer (MIRROR)

Prostate Cancer

United States
University Health Network, Toronto

Recruiting

MR-Adaptive Radiation Therapy for Anal Cancer With EScalated-Treatment in a Risk-Optimized Approach (MAESTRO)

Anal Squamous Cell Carcinoma

Canada
St. Jude Children's Research Hospital

Recruiting

Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease

Rhabdomyosarcoma

United States
HTA Co., Ltd.

Recruiting

Study of 18F-Florastamin PET/CT Imaging in Patients With at Least Intermediate Risk Prostate Cancer

Prostate Cancer

China
Niguarda Hospital

Recruiting

Ischemic And Bleeding Risk Assessment After TAVR (FOCUS ONE)

Aortic Valve Stenosis | Transcatheter Aortic Valve Replacement

Italy, Belgium, Czechia, Chile, Spain
The First Hospital of Jilin University
CSPC Ouyi Pharmaceutical Co., Ltd.

Not yet recruiting

The Efficacy and Safety of the RCMOP Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high Risk Diffuse Large B-cell Lymphoma Who Had Incomplete Remission.

Diffuse Large B-cell Lymphoma

China
Qilu Hospital of Shandong University

Recruiting

Efficacy and Safety of Pseudomonas Aeruginosa for Intermediate and High-risk Non-muscle Invasive Bladder Cancer

Bladder Cancer

China
IRCCS San Raffaele

Recruiting

24 Gy in One Fraction Urethral-sparing "HDR Like" SBRT for Prostate Cancer (PRO-FAST)

Localized Prostate Carcinoma

Italy
Turku University Hospital

Recruiting

Neoadjuvant ADT With TULSA in the Treatment of Intermediate Risk Prostate Cancer (NeoADT-TULSA)

Prostate Cancer | Localized Prostate Carcinoma | Intermediate Risk Prostate Cancer | Castration-Naive Prostate Cancer

Finland
Ottawa Hospital Research Institute
Knight Therapeutics (USA) Inc

Recruiting

Dose Escalation For INtraprostatic LEsions (DEFINE)

Prostatic Neoplasms

Canada
Fondazione del Piemonte per l'Oncologia

Recruiting

Robotic Hemi-Prostatectomy With Urethral Preservation in Low and Intermediate Risk Monolateral Prostate Cancer (RETURN)

Prostate Cancer

Italy
Genesis Research LLC

Recruiting

Investigator Initiated Trial to Further Evaluate the Safety and Efficacy of Trans-perineal Focal Laser Ablation of Localized Prostate Cancer Using High Frequency Micro-ultrasound Imaging

Prostate Cancer | Low-risk or Favorable Intermediate Risk Prostate Cancer Who Are on an Active Surveillance Regimen

United States
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not yet recruiting

Comparative Evaluation of Efficacy and Safety of Toremifene, Tamoxifen, and Aromatase Inhibitor Plus Ovarian Function Suppression in Hormone Receptor-Positive Early Breast Cancer Among Non-Low-Risk Premenopausal Women: A Real-World Study

Premenopausal Breast Cancer | Hormone-receptor-positive Breast Cancer | Breast Cancer Patients at Intermediate to High Risk | Ovarian Function Suppression Combined With Aromatase Inhibitor or Tamoxifen or Torimefen

China
University of Cincinnati
Janssen, LP

Recruiting

Focal Prostate Ablation With Androgen Deprivation and Novel Hormonal Therapy for Intermediate Risk Prostate Cancer

Prostate Cancer

United States
University of Nebraska

Recruiting

High-dose Brachytherapy Boost With Stereostatic Body Radiation Therapy to Intermediate or Higher Risk Prostate Cancer

Prostatic Cancer

United States
Case Comprehensive Cancer Center

Recruiting

eXtended Antibiotic Prophylaxis for Intermediate- and High-risk Glands After Pancreatoduodenectomy to Reduce CR-POPF

Pancreatic Fistula

United States
University Health Network, Toronto

Not yet recruiting

Long Term Cardiovascular Disease Event Risk for Patients Undergoing Major Non-Cardiac Surgery (CVD-10y-postop)

Cardiovascular Diseases | Risk Reduction Behavior
National Taiwan University Hospital

Recruiting

Ropeginterferon Alfa 2b for Early MyelofibrosisDIPSS Low/Intermediate-1 Risk Myelofibrosis

Pre-fibrotic Myelofibrosis

Taiwan
Royal Marsden NHS Foundation Trust

Recruiting

Dose De-escalation in Prostate Radiotherapy Using the MRL (DESTINATION)

Prostate Adenocarcinoma

United Kingdom
West German Study Group
AstraZeneca

Not yet recruiting

NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer (ADAPTHER2-IV)

HER2-positive Early Breast Cancer

Germany
Penumbra Inc.

Recruiting

Comparison of Two Pulmonary Embolism Treatments

Pulmonary Embolism Acute

United States
Francis Medical Inc.

Recruiting

Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer (VAPOR 2)

Prostate Cancer

United States
Qing XIe

Recruiting

A Prospective Study to Evaluate Peginterferon in Reducing the Incidence of HCC in CHB Patients

Chronic Hepatitis B | Intermediate to High Risk of HCC

China
Istituto Clinico Humanitas
Mediolanum Cardio Research

Recruiting

PBI for Breast In Situ Carcinoma of Intermediate Low Risk as Local Adjuvant Treatment (PRISCILLA)

Breast Cancer

Italy
Washington University School of Medicine
Varian Medical Systems

Recruiting

Adaptive Stereotactic Body Radiation Therapy to the Prostate and Pelvic Nodes With Simultaneous Integrated Boost to the MR-detected Nodule for Patients With High-risk and Unfavorable Intermediate-risk Prostate Cancer

Prostate Cancer | Cancer of the Prostate

United States
Al-Azhar University

Recruiting

Safety and Efficacy of Scheduled Intravesical Gemcitabine Versus Intravesical BCG for Intermediate and High Risk Non Muscle Invasive Bladder Cancer: A Prospective, Randomized Study

Non-muscle-invasive Bladder Cancer

Egypt
Assiut University

Not yet recruiting

Catheter Directed Therapy in Intermediate Risk Pulmonary Embolism Patients

Pulmonary Embolism Subacute Massive
Centre Leon Berard

Recruiting

Stereotactic Prostate Radiotherapy With Dose Escalation Focused on the "Dominant Intra-prostatic Lesion" (DIPL) Delineated by Multi-parametric MRI and 68Ga-PSMA PET (Prostate-SIB-PSMA) (Prostate-SIB)

Prostate Adenocarcinoma

France
Shaare Zedek Medical Center

Recruiting

Vyxeos for Induction of Low- or Intermediate-risk.

Leukemia, Myeloid, Acute

Israel
University of Rochester
Karyopharm Therapeutics Inc

Recruiting

Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma

Smoldering Multiple Myeloma

United States
San Carlo di Nancy Hospital
Elesta S.R.L.

Recruiting

Transperineal Laser Ablation for Low- and Intermediate Risk Prostate Cancer: a Single Cohort Analysis

Prostate Cancer

Italy
Forma Therapeutics, Inc.

Recruiting

A Study of Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)

Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R

United States, France, Canada, Germany

3

Subscribe